Physician profile
Paul Pietrow
NPI 1982709945
$3,681.40
in general payments reported to CMS, 2019-2025
34 companies · $514 in 2025
The $514 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $123 · 2021: $336 · 2022: $815 · 2023: $761 · 2024: $851 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,091 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,091.13 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| C. R. Bard, INC. & Subsidiaries | $508.30 | 2019-2024 | Bard Urinary Drainage Bag |
| Urogen Pharma, INC. | $455.65 | 2021-2025 | Jelmyto |
| Pfizer INC. | $299.38 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $268.44 | 2019-2025 | |
| Janssen Biotech, INC. | $215.02 | 2021-2025 | Erleada |
| Merck Sharp & Dohme LLC | $211.32 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $201.61 | 2019-2025 | Xtandi, Myrbetriq |
| Myriad Genetic Laboratories, INC. | $154.53 | 2021-2025 | Prolaris, Myrisk |
| Sumitomo Pharma America, INC. | $115.36 | 2024-2025 | Orgovyx |
| Abbvie INC. | $110.36 | 2019-2024 | |
| Coloplast Corp | $98.97 | 2019-2024 | |
| Antares Pharma, INC. | $96.96 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| 180 Medical, INC. | $96.44 | 2022-2024 | |
| Verity Pharmaceuticals INC. | $92.46 | 2023-2025 | Trelstar |
| Alnylam Pharmaceuticals INC. | $83.68 | 2023-2025 | Givlaari |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $75.75 | 2019-2025 | Adstiladrin |
| Astrazeneca Pharmaceuticals LP | $74.83 | 2020-2025 | Imfinzi |
| Allergan, INC. | $68.05 | 2019-2021 | |
| Endo USA, INC. | $58.63 | 2025 | Aveed, Xiaflex |
| Sun Pharmaceutical Industries INC. | $49.49 | 2022 | |
| Progenics Pharmaceuticals, INC. | $47.80 | 2022-2023 | Pylarify |
| Amgen INC. | $45.90 | 2020-2022 | |
| Telix Pharmaceuticals | $33.11 | 2024 | Illuccix |
| Rochester Medical Corporation | $29.38 | 2019-2022 | |
| Myovant Sciences INC. | $25.49 | 2021 | |
| Procept Biorobotics Corporation | $25.21 | 2023 | Aquabeam Robotic System |
| Acerus Pharmaceuticals Corporation | $20.95 | 2021 | |
| Ethicon US, LLC | $19.76 | 2025 | Surgicel Nu-Knit, Vistaseal, Stratafix |
| Tolmar, INC. | $18.31 | 2023 | |
| Palette Life Sciences, INC. | $16.59 | 2022 | |
| Olympus America INC. | $16.43 | 2023 | Itind System |
| Boston Scientific Corporation | $16.18 | 2022 | |
| Foundation Medicine, INC. | $15.56 | 2022 | |
| Laborie Medical Technologies Corp. | $15.50 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Pietrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.